This study was undertaken to evaluate the response to parenteral administration of iron in 62 pregnant patients with asiderotic anemia and mean initial hemoglobin (Hb) concentrations (Hb1) of 9.91+/-(SD) 1.13 g/dl. Iron (742+/-366 mg) was administered intravenously, and the response to treatment was classified according to the rise in Hb (VarHb; 0.97+/-0.77 g/dl) and evaluated after 19.5+/-14.6 (range 4-57) days. It was found that the VarHb was inversely correlated with the Hb1 value (r = -0.46; p<0.001) and only weakly correlated with the number of vials administered. In addition, two-cluster analysis of patients on the basis of VarHb and gestational age resulted in two significantly different groups (p<0.001): >28 weeks of pregnancy (n = 39, group 1: 1.27+/-0.66, range 0.1-3.3 g/dl) and < or =28 weeks of pregnancy (n = 23, group 2: 0.45+/- 0.69, range 0.4-2.3 g/dl). No difference was found between groups 1 and 2 in relation to Hb1, iron dose, and therapy duration. The number of patients with VarHb >0.8 g/dl was found to be higher in group 2 than in group 1: 31/39 versus 8/23 (p<0.001). These results indicate that the response to intravenous iron therapy in pregnancy anemia is related to Hb1 level and gestational age at the onset of treatment and probably depends on the erythropoietin response to anemia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000010109 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Randomized controlled trial on the treatment of Hypoferritinemia without Anemia: Comparing oral and intravenous iron supplementation among reproductive age women in Pakistan.
Pak J Med Sci
January 2025
Dr. Rubeena Zakar, MBBS, PhD Public Health, Department of Public Health, Institute of Social and Cultural Studies, University of Punjab, Lahore, Pakistan.
Background & Objectives: Hypoferritinemia without anemia (HWA) is an under-recognized public health concern. Early identification and targeted treatment of HWA can prevent unnecessary medication use and potential drug abuse. This study aims to establish clearer guidelines for recognizing and managing HWA, improving patient's outcome.
View Article and Find Full Text PDFBackground And Aims: Red blood cell transfusions are often used to treat iron-deficient patients in the emergency department (ED), while treatment with intravenous (IV) iron is preferred, as it increases hemoglobin concentration rapidly and durably. We aim to evaluate the incidence of iron deficiency anemia, frequency of blood transfusion and iron supplementation, and factors associated with blood transfusion in the ED.
Methods: We conducted a retrospective cohort study of adult patients presenting to the St.
Treatment Inertia and Symptom Burden in Anemia of CKD: Insights from the SATISFY Survey in the Middle East, South Africa, and Türkiye.
Int J Nephrol Renovasc Dis
January 2025
Astellas Pharma Singapore Pte. Ltd, Singapore, Singapore.
Introduction: Limited data exist regarding treatment patterns and symptom burden of patients with anemia of chronic kidney disease (CKD) in the Middle East, South Africa, and Türkiye.
Methods: This real-world study explored clinical characteristics, symptom burden, and treatment patterns of patients with anemia of CKD living in the Middle East, South Africa, and Türkiye. Physician and patient perceptions of treatment were captured via cross-sectional surveys; patients' clinical characteristics were recorded by retrospective review of medical records.
Efficacy and safety of intravenous ferric carboxymaltose in the treatment of Restless Legs Syndrome: a systematic review and meta-analysis.
Front Neurol
January 2025
Department of Public Health, Atish Dipankar University of Science and Technology, Dhaka, Bangladesh.
Introduction: Restless Legs Syndrome (RLS), also known as Willis-Ekbom Disease (WED), is a sensorimotor disorder characterized by an uncontrollable urge to move the legs, typically accompanied by discomfort. Low iron levels, pregnancy, and age are some identified risk factors. RLS is treated using various pharmacological options, including dopamine agonists, benzodiazepines, anticonvulsants, opioids, and bupropion.
View Article and Find Full Text PDFSafety and Efficacy of Ferric Carboxymaltose for Iron Deficiency Anemia in Inflammatory Bowel Disease: A Systematic Review.
Cureus
December 2024
Internal Medicine, California Institute of Behavioral Neurosciences and Psychology, Fairfield, USA.
Ulcerative colitis and Crohn's disease, two types of inflammatory bowel disease (IBD), often cause anemia, primarily due to iron deficiency and chronic inflammation. Anemia negatively affects patients' daily functioning and quality of life, causing symptoms including headaches, exhaustion, and dyspnea. In IBD, iron deficiency arises from reduced intake, chronic blood loss, and impaired absorption.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!